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Abstract
The final step in vitamin D activation is catalyzed by 1-alpha-hydroxylase (CYP27B1).
Chronic kidney disease (CKD) is characterized by low levels of both 25(OH)D3 and 1,25
(OH)2D3 provoking secondary hyperparathyroidism (2HPT). Therefore, treatments with
active or native vitamin D compounds are common in CKD to restore 25(OH)D3 levels and
also to decrease PTH. This study evaluates the dose of 25(OH)D3 that restores parathyroid
hormone (PTH) and calcium levels in a model of CKD in CYP27B1-/- mice. Furthermore, we
compare the safety and efficacy of the same dose in CYP27B1+/+ animals. The dose
needed to decrease PTH levels in CYP27B1-/- mice with CKD was 50 ng/g. That dose
restored blood calcium levels without modifying phosphate levels, and increased the
expression of genes responsible for calcium absorption (TRPV5 and calbindinD- 28K in the
kidney, TRPV6 and calbindinD-9k in the intestine). The same dose of 25(OH)D3 did not
modify PTH in CYP27B1+/+ animals with CKD. Blood calcium remained normal, while phos-
phate increased significantly. Blood levels of 25(OH)D3 in CYP27B1-/- mice were extremely
high compared to those in CYP27B1+/+ animals. CYP27B1+/+ animals with CKD showed
increases in TRPV5, TRPV6, calbindinD-28K and calbindinD-9K, which were not further ele-
vated with the treatment. Furthermore, CYP27B1+/+ animals displayed an increase in vascu-
lar calcification. We conclude that the dose of 25(OH)D3 effective in decreasing PTH levels
in CYP27B1-/- mice with CKD, has a potentially toxic effect in CYP27B1+/+ animals with
CKD.
Introduction
Vitamin D is a major regulator of Ca2+ and phosphate homeostasis and it is essential for
proper development and maintenance of bones.[1] The active form of vitamin D, 1,25
(OH)2D3, is synthesized from its precursor 25OHD3 by the 25-hydroxyvitamin-D-1α-
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hydroxylase (1-α-hydroxylase; CYP27B1).[2] Mutations in the CYP27B1 gene cause severe dis-
orders of Ca2+ homeostasis, including vitamin D-dependent rickets type I (VDDRI).[3]
Chronic kidney disease- mineral and bone disorder (CKD-MBD) is a common problem in
patients with kidney disease. It is characterized by abnormal levels of calcium (Ca) and phos-
phate (P) and biochemical alterations of mineral metabolism related hormones, alongside
vascular calcification. Among those biochemical alterations, low levels of active vitamin D
metabolites are of paramount importance.[4] To treat CKD-MBD related complications, vita-
min D compounds have been widely used. However, the use of active vitamin D compounds
such as 1,25(OH)2D3 has been accompanied by undesired side effects like hypercalcemia and
hyperphosphatemia, which increase the risk of vascular calcification.[5] To avoid these effects,
vitamin D analogs were developed in order to suppress PTH secretion with a minimal calce-
mic action. [6–8]
Active vitamin D compounds directly increase intestinal and renal Ca2+ reabsorption
through up-regulation of Ca2+ transport proteins.[9] A distinct family of epithelial Ca2+ chan-
nels (TRPV6 and TRPV5) has been identified, which provides the molecular identity of the
apical entry mechanism facilitating this active Ca2+ reabsorption process.[10, 11] Ca2+ entry
via these Ca2+ channels is followed by cytosolic diffusion facilitated by Ca2+ binding proteins
(calbindin-D28K and /or calbindin-D9k) and active extrusion of Ca2+ across the basolateral
membrane by a high affinity plasma membrane Ca2+-ATPase (PMCA1b) and Na+-Ca2+
exchanger (NCX1). In this active process, TRPV5 and TRPV6 probably form the final target
for hormonal control, suggesting that these channels could be the primary targets in the regu-
lation of Ca2+ reabsorption.[9]
Not only 1,25(OH)2D3, but also 25OHD3 levels are low in CKD-MBD. Due to the existence
of CYP27B1 in many tissues, international guidelines propose the correction of low 25OHD3
levels to maintain the pleiotropic beneficial effects of vitamin D.[12, 13] Thus, the use of chole-
calciferol or even 25OHD3 to correct its own deficiency has been recommended.[14] Further-
more, the normalization of 25OHD3 levels has been reported to have an effect in decreasing
PTH levels.[15] It has been also shown that 25OHD3 can mediate its effects independent of its
conversion to 1,25(OH)2D3.[16] However, it is unknown whether the effect of 25OHD3 on
PTH reduction is achieved directly by activation of VDR or by residual conversion into 1,25
(OH)2D3.
The hypothesis of the present study is that the dose necessary to decrease PTH with
25OHD3 (without conversion into 1,25(OH)2D3) in CKD is very high, and could have toxic
effects. Thus, the aim of the present study was to find the dose of 25OHD3 effective enough
to restore Ca2+ and PTH levels in a CYP27B1 knockout (CYP27B1-/-) mouse model with
CKD, therefore independently of conversion into 1,25(OH)2D3, and to test the same dose in
CYP27B1+/+ mice to evaluate its safety and efficacy in decreasing PTH. We also investigated
the effects of 25OHD3 treatment in regulating the expression of the main genes responsible
for intracellular and paracellular calcium transport in the kidney and intestine of the same
mice.
Methods
In Vivo study
All animal studies were approved by the University of Lleida Animal Ethics Committee in
accordance with the guidelines of European Research Council for the care and use of labora-
tory animals. In all surgical procedures performed in animals, isoflurane was used as anesthetic
and buprenorphine was used as analgesic after the surgery.
25(OH)D in Experimental CKD
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Generation and characterization of CYP27B1-/- mice
CYP27B1-/- mice were provided by Dr. David Goltzman (Montreal, Canada) and were gener-
ated by ablation of exon 6 to exon 9 (26). These mice were bred to C57/BL6 wild-type animals
and the heterozygous offspring were crossed to produce CYP27B1-/- (KO) and CYP27B1+/+
(WT) animals. KO mice were fed a rescue diet (2% calcium, 1.25% phosphorus, 20% lactose
and 2.2 IU/g vitamin D3; Harlan Teklad, TD.96348) during growth and maintenance. Before
starting the experimental process the diet was changed to a standard mouse chow for KO ani-
mals (0.6% Ca2+, 0.8% phosphorus, and 0.6 IU/g vitaminD3; Harlan Teklad), while WT ani-
mals were maintained on a 0.9% phosphorus diet in order to induce an increase in PTH
levels.
Model of CKD in mice
Subtotal nephrectomy was performed in 10 week-old mice after the two-step surgical proce-
dure for 75% nephron reduction (NX), as previously described. [17] Briefly, the parenchyma
of the left kidney was reduced 50%. The kidney was exposed, decapsulated and carefully cau-
terized, reducing the parenchyma of the upper and the lower pole. After 1-week of recovery
period, right-sided total nephrectomy was performed. Treatments started two weeks after
nephrectomy to facilitate recovery after the operation.
First, a dose response analysis was carried out in 10 week–old nephrectomized CYP27B1-/-
mice (KO NX) using 25, 50, 100 ng/g of 25OHD3 (Sigma-Aldrich) administered intraperitone-
ally three times per week for 30 days (n = 8 per dose). Terminal blood samples were taken 24
hours after the last injection. In parallel, an additional group of KO NX mice (n = 8) was
treated with a dose of 1,25(OH)2D3 (50 pg/g) three times per week for 30 days and a terminal
blood sample was taken 24 hours after the last injection. The goal was to determine the dosage
of 25OHD3 that induced changes in PTH levels similar to those achieved with 1,25(OH)2D3.
After selecting the dosage of 50 ng/g for 25OHD3, nephrectomized CYP27B1
+/+ mice (WT
NX, n = 8) were treated with the same dose and route of administration for a 30 days period. A
group of sham-operated mice were used as a control in the present study (CYP27B1+/+ (WT
control) n = 6, CYP27B1-/- (KO control) n = 5).
Euthanasia was performed 24 hours after the last injection. Then, a terminal blood sample
was collected and aortas were divided in two parts, one frozen in liquid nitrogen for calcium
content determination and the other one fixed in formalin solution followed by processing
and paraffin embedding. Kidney and duodenum were collected to study the expression of cal-
cium transport proteins.
Serum biochemical analysis
Blood was collected by cardiac puncture and centrifuged at 2500 rpm for 10 min at 4˚C to
obtain serum.
Ca2 + and P were analyzed by a standard colorimetric assay analysis in the Biochemistry ser-
vice of the Arnau de Vilanova Hospital (HUAV) in Lleida using a multichannel autoanalyzer
(Roche/Hitachi Modular Analytics), using the following methods: 1) for calcium the o-cre-
solphthalein complexone method, 2) for phosphate the ammonium molybdate method. Blood
urea nitrogen (BUN) was determined by colorimetric assay using the QuantiChrom Urea
assay kit (DIUR-500, Gentaur, San Jose, CA, USA). Immunoassays were used to determine
25OHD3, 1,25 (OH)2D3 (IDS 25OHD3 EIA, Immunodiagnostic Systems, The Boldons, UK),
and also PTH (PTH mouse ELISA kit, Immunotopics, San Clemente, CA, USA).
25(OH)D in Experimental CKD
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Quantitative analysis of aortic calcium
Aortic tissue was desiccated for 20–24 hours at 60˚C, crushed to a powder with a pestle and
mortar, and decalcified with HCl (1N) at 4˚C, and then vortexed for 16 hours. After centrifu-
gation, supernatant was collected and calcium content determined colorimetrically using the
o-cresolphthalein complexone method, whereas total protein content was determined by the
Lowry method (Bio-Rad, Hercules, CA, USA), as previously described.[7] Aortic calcium con-
tent was normalized by the protein amount in the sample and expressed as ng of Ca/ mg of
protein.
Histology and immunohistochemistry
Immunostaining for CalbindinD28k and TRPV5 were carried out on 5-μm-thick kidney tissue
sections. Sections were deparaffinized through xylene and rehydrated through graded ethanol
concentrations into distilled water, as previously described.[18] Shortly, antigen retrieval was
done by boiling the slides in 10mM citrate buffer (pH 6) for 10 minutes. Endogenous peroxi-
dase quenching (30 min incubation in 0.66% (vol/vol) H2O2/PBS) was followed by blocking of
nonspecific binding with normal horse blocking serum (Vector Laboratories) for 30 min at
room temperature (RT). Anti-rabbit calbindinD28k (1:500) and anti-guinea pig TRPV5 anti-
body (1:1500) were incubated overnight at 4˚C. After washing with PBS, slides were treated
with goat anti-rabbit Alexa 488 (1:300) (for CalbindinD28k) and Cy2 AffiniPure donkey anti-
guinea pig IgG (1:150) (for TRPV5) for 1 hour at RT. Sections were dehydrated in methanol
and mounted with Mowiol. Negative controls were performed by incubation with nonimmune
serum in place of a specific antibody, which resulted in complete absence of staining. Images
were taken with Zeiss fluorescence microscope with a digital camera (Nikon DMX1200).
For calcium staining in aortic sections, samples were deparaffinized, rehydrated and stained
in 2% Alizarin red solution (Sigma A3757, Sigma Aldrich, SL, MO, USA) at pH between 4,1–
4,3 for 5 min. After staining, samples were rehydrated with acetone, acetone-xylene (1:1),
xylene and mounted in synthetic mounting medium (DPX, Sigma Aldrich, SL, MO, USA).
Real time PCR
Total RNA was extracted from the kidney and duodenum samples using TRIzol reagent
(Sigma Aldrich, SL, MO, USA) and following manufacturer’s instructions. The RNA concen-
trations were determined by nanodrop (ND-100) spectrophotometer. Reverse transcription
was performed as previously described.[19] Real time PCR with gene-specific SYBR Green
primers for mouse TRPV5 (5’CTGGAGCTTGTGGTTTCCTC3’), Calbindin-D28k (5’GACG
GAAGTGGTTACCTGGA3’), Calbindin-D9k (5’CCTGCAGAAATGAAGAGCATTTT3’),
PMCA1b (5’GTCACCGGCCTTACGTGTAT3’), NCX1 (5’GTGACTGCCGTTGTGTTTGT3’),
TRPV6 (5’GGCCTCACAACCTCATTTAC3’) and GAPDH (5’TAACATCAAATGGGGTGAG
G3’) was performed with a CFX Real-Time PCR detection system (Bio-Rad Laboratories, S.
A., Madrid, Spain). Forty cycles at 95˚C for 15 seconds and 60˚C for 1 minute were per-
formed. Duplicate readings were taken, and the average was calculated. The relative mRNA
levels were calculated by standard formulae (ΔΔCt method) using mouse GAPDH as an
endogenous control. The results referred to a randomly selected basal sample that was consid-
ered as value = 1.
Western blot analysis
Kidney tissue was homogenized in lysis buffer (50 mM HEPES, 250 mM NaCl, 5 mM EDTA,
0,1% Nonidet P-40) using polytron homogenizer. After centrifugation for 10 min at 10000
25(OH)D in Experimental CKD
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rpm, 4˚C, supernatant was collected and protein concentration was determined using a BCA
protein assay kit (Bio-Rad). 25μg of proteins were electrophoresed on 12% SDS-PAGE gels
and transferred to PVDF membranes (Immobilon-P, Millipore), as previously described.
[20] Membranes were probed with primary antibodies against CalbindinD28k (1:10000) and
α-tubulin (1:5000) over night at 4˚C. Appropriate horseradish peroxidase-conjugated sec-
ondary antibodies were used at 1:10000. The immunoreaction was visualized using chemilu-
minescent kits EZ ECL (Biological Industries) or ECL Advanced (Amersham Biosciences).
Images were digitally acquired by Chemidoc (Bio Rad). Positive immunoreactive bands were
quantified by densitometry and compared with the expression of adequate loading control
(α-tubulin).
Statistical analysis
Differences between groups were assessed by one-way ANOVA and Bonferroni posthoc test.
Differences between WT and KO mice were assessed by two-way ANOVA and Bonferroni
posthoc test. A p<0.05 was considered statistically significant. All data examined are expressed
as mean ± SEM.
Results
25OHD3 restores calcium and PTH levels in CYP27B1-/- mice with CKD
We first sought to determine the dose of 25OHD3 effective enough to maintain serum Ca
2+
and PTH levels in CYP27B1-/- mouse model with CKD. CYP27B1-/- (KO) mice were subjected
to subtotal nephrectomy (KO NX) and treated with 25, 50 and 100 ng/g of 25OHD3 three
times per week for 30 days. The dose of 25OHD3 that was able to normalize serum Ca
2+ and
reduce PTH levels in KO NX animals similar to 1,25OH2D3 (50 pg/g) was 50 ng/g of 25OHD3
(S1 Fig). This dose was chosen for further investigation in CYP27B1+/+ (WT) and CYP27B1-/-
(KO) mice. After subtotal nephrectomy, serum BUN levels increased in all nephrectomized
groups of mice (Fig 1A), suggesting a similar degree of renal impairment. Calcium levels (Fig
1B), generally lower in KO mice (both in normal and NX conditions), increased with 25OHD3
treatment reaching similar levels as in WT animals. Neither nephrectomy nor 25OHD3 treat-
ment did modify serum calcium levels of WT animals (Fig 1B). Phosphate levels, which were
comparable in control and NX groups of mice, significantly increased only in WT NX animals
treated with 25OHD3 (Fig 1C). Levels of PTH, which are very high in KO mice, increased even
more after the nephrectomy and were partially corrected in KO NX mice after the treatment
with 25OHD3 (Fig 1D). 25OHD3 had no effect on elevated PTH levels in WT NX mice (Fig
1D). Serum levels of 25OHD3 increased in both groups of mice treated with 25OHD3, but
were higher in KO than in WT mice (Fig 1E). Circulating 1,25OH2D3 levels slightly increased
in WT animals treated with 50 ng/g of 25OHD3 (WT NX: 69.49 ± 23.9; WT NX+25OH:
81,64 ± 15 pg/ml. p:0.6).
25OHD3 does not induce vascular calcification in CYP27B1-/- mice with
CKD
The effect of 25OHD3 on vascular calcification in WT and KO mice is shown in Fig 2. Treat-
ment with 25OHD3 showed a tendency to increase calcium content in arteries of WT mice
(Fig 2A), but did not modify calcium content in KO animals. Representative histochemical
alizarin red staining from aortas showed an increase of the staining in the elastic laminas of
WT mice treated with 25OHD3 (Fig 2B).
25(OH)D in Experimental CKD
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Fig 1. 25OHD3 restores calcium and PTH levels in CYP27B1-/- mice with CKD. A: BUN B: Calcium C:
Phosphate D: PTH and E: 25OHD3 serum levels from CYP27B1+/+ (WT) and CYP27B1-/- (KO) control mice,
nephrectomized (nx) and nephrectomized treated with 50 ng/g of 25(OH)D3 for 1 month. Data are
mean ± SEM * p< 0,001 vs. WT, # p< 0,05 vs. Control, † p< 0,05 vs. Nx, (n = 5 to 7).
doi:10.1371/journal.pone.0170654.g001
Fig 2. 25OHD3 does not induce vascular calcification in CYP27B1-/- mice with CKD. A: Calcium content
in abdominal aorta normalized to protein in CYP27B1+/+ (WT) (white bars) and CYP27B1-/- (KO) control mice,
nephrectomized (nx) and nephrectomized treated with 25OHD3 (50ng/g) for 1 month. B: Representative
histochemical of alizarin red staining from aortas of mice from the same groups. Data are mean ± SEM (n = 5
to 7) * p< 0,001 vs WT mice. † p< 0,05 vs. nx.
doi:10.1371/journal.pone.0170654.g002
25(OH)D in Experimental CKD
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25OHD3 increases expression of TRPV6 and Calbindin-D9k in
duodenum of CYP27B1-/- mice with CKD
We further investigated whether treatment with 25OHD3 had influence on the expression of
genes encoding Ca2+ transport proteins involved in duodenal transcellular Ca2+ absorption.
Administration of 50 ng/g of 25OHD3 produced a 3-fold increase in TRPV6 mRNA in KO NX
mice, while in WT animals the increase of TRPV6 mRNA was already evident after the
nephrectomy and did not further increase with the treatment (Fig 3A). Calbindin-D9k mRNA
levels showed a similar profile (Fig 3B). The expression of PMCa1b mRNA was not signifi-
cantly modified by any of the conditions (Fig 3C).
25OHD3 increases expression of Ca2+ transport genes and proteins in
the kidney of CYP27B1-/- with CKD
The effect of 25OHD3 on mRNA expression of Ca
2+ transport genes (TRPV5, Calbindin-
D28k, NXC1 and PMCA1b) in the kidney was investigated by real-time quantitative PCR. The
profile of Calbindin-D28k mRNA expression in the kidney was similar to the expression of
Calbindin-D9k mRNA in the duodenum. Namely, nephrectomy (NX) increased Calbindin-
D28k mRNA expression in the kidneys of WT mice, which was not further increased by
25OHD3 treatment (Fig 4A). On the contrary, nephron reduction in KO mice did not modify
the expression of Calbindin-D28k mRNA, but the treatment with 25OHD3 managed to
increase the expression of this gene in the kidney, although to the levels lower than in WT ani-
mals (Fig 4A). Analysis of protein expression, determined by Western blot (Fig 4B), corrobo-
rated results obtained by RT-PCR analysis. Furthermore, immunofluorescence analysis
showed an increase of Calbindin-D28k staining in distal tubules of KO NX mice treated with
25OHD3 (Fig 4C).
Fig 3. 25OHD3 increases expression of TRPV6 and Calbindin-D9k in duodenum of CYP27B1-/- mice
with CKD. A: TRPV6 B: Calbindin-D9K and C: PMCA1b mRNA expression (qPCR) in CYP27B1+/+ (WT) and
CYP27B1-/- (KO) control mice, nephrectomized (nx) and nephrectomized treated with 25OHD3 for 1 month.
Data are mean ± SEM * p< 0,001 vs. WT, # p< 0,05 vs. Control, † p< 0,05 vs. Nx, (n = 5 to 7).
doi:10.1371/journal.pone.0170654.g003
25(OH)D in Experimental CKD
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Expression of TRPV5 significantly increased in the WT group after the NX and did not fur-
ther increase with the 25OHD3 treatment (Fig 5A). In the KO group, NX did not modify the
expression of TRPV5 mRNA, but the treatment with 25OHD3 was able to increase the expres-
sion of this gene (Fig 5A). Immunofluorescence analysis showed an increase of TRPV5 stain-
ing in distal convoluted and connecting tubules of KO NX mice treated with 25OHD3 (Fig
5B). Expression of the basolateral extrusion genes (NCX1 and PMCA1b) was not affected by
25OHD3 (Fig 6A and 6B) in KO NX mice. Nevertheless, WT NX mice showed an increase of
PMCA1b mRNA expression after administration of 25OHD3 treatment (Fig 6A), while the
expression of NCX1 increased in the both WT NX groups (untreated and treated with
25OHD3) (Fig 6B).
Discussion
In the present paper we demonstrate that the suppression of PTH in an experimental model of
CKD can be achieved directly by 25OHD3 without its conversion to 1,25(OH)2D3, but the
blood levels necessary to attain the effect are extremely high. Furthermore, although the effect
is undoubtedly due to an effect of 25OHD3, it is unclear whether this effect is directly stimulat-
ing VDR in the parathyroid gland or indirectly by increasing calcium absorption in the intes-
tine. Thus, the administration of 50 ng/g of 25OHD3 in KO NX animals decreased serum PTH
to levels below the ones observed in the same animals with normal renal function. This inhibi-
tion was achieved with blood levels of 25OHD3 around 7 times higher than the normal levels
and in parallel to a normalization of blood calcium levels. Thus, the decrease of PTH could be
attained by a combination of normalization of blood calcium levels and direct activation of
VDR by 25OHD3 in the parathyroid gland.
Fig 4. 25OHD3 increases expression of CalbindinD-28K in the kidneys of CYP27B1-/- mice with CKD.
A: mRNA expression (qPCR) B: protein expression (western blot) and C: immunohistochemistry of
CalbindinD-28K in CYP27B1+/+ (WT) and CYP27B1-/- (KO) control mice, nephrectomized (nx) and
nephrectomized treated with 25OHD3 for 1 month. Data are mean ± SEM * p< 0,001 vs. WT, # p< 0,05 vs.
Control, † p< 0,05 vs. Nx, (n = 5 to 7).
doi:10.1371/journal.pone.0170654.g004
25(OH)D in Experimental CKD
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The results of the present study demonstrate that 25OHD3 can activate VDR in uremic con-
ditions, and agree with previous results showing similar results in animals with normal renal
function.[21] It has been shown that uremic milieu contains toxins that block the binding of
activated VDR with VDRE in the promoter of target genes.[22] Thus, inhibition of VDR target
gene expression by uremia can partially explain the resistance to 1,25(OH)2D3 observed in
CKD. Our results show that reaching levels of 25OHD3 in blood high enough can overcome
the mentioned problem. We demonstrate that treatment with 25OHD3 increased the expres-
sion of calcium channels in the kidney and intestine, most likely by direct effect of activated
VDR on the promoter of target genes.
Furthermore, the administration of the same dose of 25OHD3 to WT NX animals showed
interesting results. Namely, the dose administered was unable to significantly reduce the
increase of PTH levels induced by the nephrectomy and high phosphate feeding. Although the
PTH levels obtained with the nephrectomy in WT NX animals were far lower than measured
Fig 5. 25OHD3 increases expression of TRPV5 in the kidneys of CYP27B1-/- mice with CKD. A: mRNA
expression (qPCR) and B: immunohistochemistry of TRPV5 in CYP27B1+/+ (WT) and CYP27B1-/- (KO)
control mice, nephrectomized (nx) and nephrectomized treated with 25OHD3 for 1 month. Data are
mean ± SEM * p< 0,001 vs. WT, # p< 0,05 vs. Control, † p< 0,05 vs. Nx, (n = 5 to 7).
doi:10.1371/journal.pone.0170654.g005
25(OH)D in Experimental CKD
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in KO NX animals, there are similar to the ones found in CKD patients.[23] In any case, this
different behavior of the treatment could be due to two reasons. On the one hand, the levels of
25OHD3 achieved in blood of WT NX mice were much lower than the ones observed in the
KO NX animals. This effect could be explained by a higher rate of degradation of 25OHD3 or
by its conversion to 1,25(OH)2D3. The degradation of both, 1,25(OH)2D3 and 25OHD3 is
mediated by the enzyme 24-hydroxylase, the levels of which are highly induced by active vita-
min D compounds.[24] Thus the levels of 24-hydroxylase are expected to be very low in the
KO animals, increasing the half-life of the 25OHD3 and its blood concentration. Furthermore,
and in contrast to KO mice, part of the 25OHD3 administered to the WT animals can be con-
verted to 1,25(OH)2D3, which will also decrease 25OHD3 levels. Although this represents a
very small portion of 25OHD3, the circulating levels of 1,25(OH)2D3 did not significantly
increase, it could also have an influence on 25OHD3 blood levels. On the other hand, the
administration of 25OHD3 to the WT animals induced an increase in the levels of phosphate
which have been shown to stimulate PTH synthesis and release.[25] This effect can also be
explained by the partial conversion of 25OHD3 into 1,25(OH)2D3 and subsequent activation
of intestinal VDR, which has been shown to increase phosphate absorption from the intestine,
although this effect should minor since circulating levels of 1,25(OH)2D3 did not significantly
increase.[26]
Furthermore, the administration of the same doses of 25OHD3, although ineffective to
decrease PTH levels, showed a tendency to increase vascular calcification. Thus, calcium levels
in arteries of WT NX animals treated with 25OHD3 were significantly increased compared to
the treated KO NX mice. The Alizarin red staining, although not showing an evident increase
Fig 6. The effect of 25OHD3 on the expression of renal PMCA1b and NCX1 in CYP27B1+/+ and
CYP27B1-/- mice. A: mRNA expression (qPCR) of PMCA1b and B: NCX1 in CYP27B1+/+ (WT) and
CYP27B1-/- (KO) control mice, nephrectomized (nx) and nephrectomized treated with 25OHD3 for 1 month.
Data are mean ± SEM * p< 0,001 vs. WT, # p< 0,05 vs. Control, † p< 0,05 vs. Nx, (n = 5 to 7).
doi:10.1371/journal.pone.0170654.g006
25(OH)D in Experimental CKD
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in vascular calcification, showed an increase in the red staining of the elastic laminas, suggest-
ing an increase in calcium deposition in that area. The involvement of elastic lamina in medial
calcification in patients, although challenged in the past, seems to be accepted nowadays.[27,
28] This pattern is also found in some genetically modified mice affected by extensive medial
vascular calcification.[29, 30] The increase of vascular calcification in WT animals can be
explained by the increase in P levels. It has been shown that high P levels are of paramount
importance in the genesis of vascular calcification. Thus, increases in blood P have been
shown to be associated with vascular calcification both in patients and in experimental ani-
mals.[31] Furthermore, a recent paper from our laboratory has shown that the upregulation of
local CYP27B1 in the vascular smooth muscle cells is of paramount importance in the genesis
of uremic vascular calcification.[17] Thus, in KO animals the absence of CYP27B1 blocks the
increase in vascular calcification. However, in WT animals the administration of 25(OH)D3
could exacerbate the pro-calcificant effects of uremia by increasing the substrate for local pro-
duction of 1,25(OH)2D3 in the artery.
We have also shown an effect of the uremia and the treatment with 25OHD3 on the
expression of the proteins related to calcium transport both in the duodenum and in the kid-
ney. The effect of the 25OHD3 treatment on the expressions of TRPV5, TRPV6, calbindins
D9K and 28K in KO NX animals was similar. Thus NX did not have an effect of the levels of
any of the proteins, but the treatment with 25OHD3 significantly increased its expression.
Several VDRE have been identified in both TRPV and calbindin gene promoters.[32–35]
Thus, the extremely high levels of 25OHD3 reached in the treated KO NX animals could be
able to activate the VDRE in the promoter of the genes. In the WT animals however, the NX
already increased the expression levels of all four genes. The effect of CKD on renal calcium
transporter has been recently described.[36] The increase of proteins related to calcium
transport has been attributed to a possible effect of PTH, FGF23 or even vitamin D. Our
results show that active vitamin D must be playing a central role in this increase, because the
effect is absent in KO animals. Furthermore, this is the first report showing that experimental
CKD also induces an increase in duodenal calcium transport mechanisms. In the WT NX
animals, the increase of expression of all four genes was not further induced by the adminis-
tration of 25OHD3, either because the expression was already submaximal or because the
levels of 25OHD3 achieved in the WT NX animals were insufficient to further increase the
promoter activity of those four genes. The effects of uremia and the treatments on NCX1 fol-
lowed a similar pattern. However, the expression of PMCA1b on both tissues was not
affected in the same way, suggesting a different regulation of this gene. Thus, and in agree-
ment with previous results, renal levels were increased by treatment with vitamin D.[37]
However, intestinal levels of PMCA1b were not affected in any of the conditions confirming
that, as it has been suggested previously, vitamin D effects on PMCA1b gene could be tissue
specific.[38]
As any study in genetically modified animals, the main strength of the study relays in the
fact that we can be absolutely sure that all the effects observed in the treatments are due to a
direct effect of 25OHD3, as conversion to the active metabolite is totally blocked. The main
limitation is that we did not collect parathyroid glands in the treated animals, and we can not
differentiate whether the PTH reduction effect is mediated by direct effects on VDR in the
parathyroid gland or in intestinal cells.
In conclusion, 25OHD3 is able to reduce PTH in a CYP27B1
-/- mouse model of CKD with-
out direct conversion to active vitamin D, but the blood levels needed are extremely high.
Although this effect on PTH is due to an increase of VDR signaling by 25OHD3, it could be a
combination of a direct effect in the parathyroid gland and an induction of the calcium
absorption machinery in the intestine, and the subsequent normalization of Ca blood levels.
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Supporting Information
S1 Fig. Preliminary dose-response experiments. Levels of Ca (A), P (B) and PTH (C) in
sham-operated KO animals, NX KO animals and NX KO animals treated with 50 pg/g of 1,25
(OH)2D3 or 25, 50 and 100 ng/g of 25OHD3.
: p<0.01 vs KO sham. #: p<0.01 vs KO NX.
(TIF)
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